Adjuvant Moderately Hypofractionated Intensity-modulated Radiotherapy for Cervical Cancer
Recruiting now · Not applicable
Conditions studied: Hypofractionated Radiotherapy, Intensity-modulated Radiotherapy, Cervical Cancers
In brief
To investigate the safety and efficacy of moderately hypofractionated intensity-modulated radiotherapy in the treatment of postoperative cervical cancer
Key facts
- Study ID
- NCT07684508
- Run by
- Manni Huang
- People needed
- 154
- Starts
- 2026-07-10
- Expected to finish
- 2030-12-30
- Last updated by the study team
- 2026-08-05
Who can join
Age: 18 and older, up to 75. Sex: female. Healthy volunteers: not accepted.
You may qualify if…
- ECOG performance status 0 or 1;
- Histologically confirmed cervical squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma;
- Status post radical hysterectomy with pelvic lymph node dissection with or without para-aortic lymph node dissection, and postoperative radiotherapy initiated within 3 months;
- For squamous cell carcinoma: meeting Sedlis criteria; for adenocarcinoma and adenosquamous carcinoma: meeting the "four-factor model";
- Bone marrow function: white blood cell (WBC) count ≥3.0×10⁹/L, neutrophil count (NEUT) ≥1.5×10⁹/L, platelet count (PLT) ≥80×10⁹/L, hemoglobin (Hb) ≥90 g/L; renal function: normal or serum creatinine (SCr) ≤1.5×upper limit of normal (ULN) or creatinine clearance ≥50 ml/min; hepatic function: total bilirubin (TBIL) ≤1.5×ULN, aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤2.5×ULN;
- Voluntarily signed the informed consent form prior to study enrollment.
You may not qualify if…
- History of active malignant tumor within 3 years prior to initial treatment（except for the cervical cancer）and any locally curable tumors treated with radical therapy;
- Any high-risk factor confirmed by postoperative pathology: positive lymph node metastasis, positive parametrial invasion, or positive resection margin;
- History of neoadjuvant therapy prior to enrollment;
- Local recurrence or distant metastasis prior to enrollment;
- Postoperative intestinal obstruction or intestinal adhesion;
- Severe cardiac, cerebral, hepatic, or renal disorders;
- Long-term immunocompromised state;
- Pregnant or lactating females;
- Premature discontinuation of treatment for any reason;
- Poor compliance, unwillingness to participate, or inability to cooperate with follow-up;
- Any other conditions deemed unsuitable for this trial by the investigator.
Where it is running
- Cancer Hospital, Chinese Academy of Medical Sciences — Beijing, Beijing Municipality, China (enrolling)
- Lang Fang Campus of Cancer Hospital, Chinese Academy of Medical Sciences — Langfang, Hebei, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.